PBRM1 and nonpapillary renal cell carcinoma: The present study indicated that WDR72 could serve as a novel biomarker for predicting the outcome for patients treated with Nivolumab and WDR72 expression combined with PBRM1 mutation could be more persuasive to predict response for Nivolumab in ccRCC patients.